All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Laurent Garderet, Hôpital Pitié-Salpêtrière, Paris, FR. We asked, Is it safe to perform ASCT in patients with renal insufficiency?
Is it safe to perform ASCT in patients with renal insufficiency?
In this video, Garderet gives a preliminary analysis on a prospective study looking at transplant-related mortality, renal function, and toxicity in patients with multiple myeloma and renal failure. He concludes that it is now safe to perform autologous stem cell transplantation (ASCT) in patients with severe renal failure that are on dialysis at the time of transplant.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox